A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
2012 · New England Journal of Medicine · 2,004 citations
https://doi.org/10.1056/nejmoa1110557
W
William Sun
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
140
Papers
8.0K
Citations
39
h-index
80
i10-index
William Sun is an academic researcher from National Taiwan University. The author has contributed to research in topics: Myeloproliferative Neoplasms: Diagnosis and Treatment & Chronic Myeloid Leukemia Treatments & Neuroscience and Neuropharmacology Research. The author has an h-index of 39, co-authored 119 publications.
ORCID: 0000-0003-3279-7408Papers by this author
worksProbiotic neoantigen delivery vectors for precision cancer immunotherapy
2024 · Nature · 119 citations
https://doi.org/10.1038/s41586-024-08033-4
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
2018 · Journal of Hematology & Oncology · 81 citations
https://doi.org/10.1186/s13045-018-0585-5
CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation
2016 · Cancer Letters · 73 citations
https://doi.org/10.1016/j.canlet.2016.10.033
Molecular design of the N-methyl-D-aspartate receptor binding site for phencyclidine and dizolcipine.
1995 · Proceedings of the National Academy of Sciences · 46 citations
https://doi.org/10.1073/pnas.92.17.8021
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I
2017 · Clinical Lymphoma Myeloma & Leukemia · 25 citations
https://doi.org/10.1016/j.clml.2017.05.015
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat